SCHEMBL23210732

SCHEMBL23210732

[2H]C([2H])([2H])Oc1cnc2cnn(C(c3ccccc3)(c3ccccc3)c3ccccc3)c2c1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.34
GRIN2B Q13224 6/20 0.34
ACSS2 Q9NR19 5/20 0.33
MAPK1 P28482 2/20 0.33
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
HTT P42858 1/20 0.32
MAPK10 P53779 1/20 0.32
NCOA1 Q15788 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
PDGFRB P09619 1/20 0.30
PDGFRA P16234 1/20 0.30
GABRA1 P14867 2/20 0.30
GABRG2 P18507 2/20 0.30
GABRB3 P28472 2/20 0.30
GABRA5 P31644 2/20 0.30
GABRA3 P34903 2/20 0.30
GABRA2 P47869 2/20 0.30
GABRA6 Q16445 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23210847 0.92 GRIN1 (0.40) GRIN1GRIN2BACSS2MAPK1ALDH1A1
SCHEMBL23210941 0.84 ACSS2 (0.43) GRIN1GRIN2BACSS2
SCHEMBL23236599 0.83 GRIN1 (0.33) GRIN1GRIN2BMAPK1
SCHEMBL23210813 0.81 GRIN1 (0.38) GRIN1GRIN2BMAPK1
SCHEMBL23211080 0.78 ACSS2 (0.33) ACSS2
SCHEMBL23210874 0.77 ACSS2 (0.33) ACSS2MAPK1
SCHEMBL19949786 0.76 GRIN1 (0.37) GRIN1GRIN2BHTTGABRA1GABRG2
SCHEMBL23210984 0.76 GRIN1 (0.36) GRIN1GRIN2B
SCHEMBL23210907 0.73 CTSA (0.33) ACSS2
SCHEMBL30308766 0.72 MAPK1 (0.34) MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2023-10-26 US disclosed
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2023-03-21 US disclosed
EP-4045151-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS Incyte Corporation (US) 2022-08-24 EP disclosed
WO-2021076602-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION (US) 2021-04-22 WO disclosed
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2021-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 GRIN1 2634/4885GRIN2B 2843/4885ACSS2 1385/4885
US-20210106588-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GRIN1 2634/4885GRIN2B 2843/4885ACSS2 1385/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GRIN1 2634/4885GRIN2B 2843/4885ACSS2 1385/4885
US-11607416-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 GRIN1 2634/4885GRIN2B 2843/4885ACSS2 1385/4885
US-20230338389-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GRIN1 2634/4885GRIN2B 2843/4885ACSS2 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.